User:Mr. Ibrahem/Burosumab

Burosumab, sold under the brand name Crysvita, is a medication used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. It may be used in those over 5 months old. It is given by injection under the skin.

Common side effects include fever, pain at the site of injection, cough, headache, restless leg syndrome, cavities, and tooth abscess. Other side effects may include allergic reactions, high phosphate, and nephrocalcinosis. Safety in pregnancy is unclear. It is a monoclonal antibody that binds to and blocks the protein FGF23, allowing the kidneys to reabsorb phosphate.

Burosumab was approved for medical use in the United States and Europe in 2018. In the United States 30 mg costs about 12,200 USD as of 2022.